Working with eXroid
We are looking for new international partners
Global demand
Haemorrhoid disease affects everyone over their life span and it is reported that >10% of the global population are actively suffering at any one time. Many people seek over the counter help but shy away from procedures due to the fear of pain and being mobility restricted after surgery. eXroid®️ is proving to be a 'Life Changing' option for patients who can be treated and return to normal duties, often on the same day.
eXroid is now expanding globally as a result of it's highly successful clinical treatment business in the UK. We are looking to engage with Medical Device distributors who share our values, and are highly motivated and dynamic to bring this revolutionary treatment to market across the globe. We aim to provide a highly profitable and high demand addition to the colorectal portfolios of our business partners and customers.
If you are interested in working with eXroid, either as a distribution partner or clinician, get in touch with us to find out how we are working to get access to this innovative medical device globally.
Call us on 0800 999 3777 (option 4) or complete a contact form.
Our current territories
The eXroid treatment
The majority of eXroid patients say that this straightforward procedure incurs minimal or no discomfort and over 90% of patients report that they are able to return to their daily activities on the same day as treatment.
The treatment is also unique as it:
1. Treats all four grades of internal Haemorrhoids
2. Is low risk and fully ambulatory, i.e., patients can walk-in, walk-out with no bowel prep and no anaesthesia.
3. Is highly convenient, being performed along with a consultation and examination within an hour-long appointment.
homepage benefits
Clinical efficacy
Since eXroid’s launch in 2019, we have collected all data relating to the >6000 treatments for all 4 grades of haemorrhoid.
An abstract summarising the information from the first 812 patients treated was accepted by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) for presentation at their annual conference in July 2021 and has now been published in the September 2021 edition of the medical journal, Colorectal Disease. It details a very compelling case for the safety and tolerability of the eXroid treatment.
In addition, a further abstract outlining the use of our copyrighted diagnostic tool, the eXroid Clockface Assessment Tool (eCAT), has also been accepted and has been published in the same journal. Furthermore, 3 more abstracts have been accepted by the European Society of Coloproctology (ESCP), and were presented as e-posters at the September (virtual) annual conference. These abstracts are to be published in due course.
These highlight the safety of eXroid treatment for all 4 grades of internal haemorrhoids, including those patients taking anticoagulant or antiplatelet treatments, with a very low risk of bleeding or other complications when compared to the published figures for other commonly performed treatments.
Complete a contact form to receive a downloadable copy of the Treatment Brochure.
An accelerated 'go to market' business model
As eXroid has run and rapidly grown patient demand and a clinical provision service in the UK, we have blueprinted our continually evolving model to benefit our business partners achieve engagement, and scale up in an accelerated period as a result of our learning and process development and support packages.
Stage 1. Joint scoping of the market and business opportunity
Stage 2. Set out the business processes and provide critical engagement materials and support to our partner
Stage 3. Clinical engagement and training of leading and Key Opinion Leaders
Stage 4. Evaluation of clinical outcomes and roll out support
Stage 5. Market development and marketing support